Inclusion Criteria:

- Multiple myeloma. Eligible patients may have early or relapsed disease. Patients
must have Stage II-III disease or have progression after initial treatment of Stage I
disease.

- Age less than or equal to 70 years.

- No prior therapy which would preclude the use of low-dose total body irradiation.

- Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
University Medical Center. Patients with smoldering multiple myeloma, monoclonal
gammopathy of unknown significance, or primary amyloidosis will be excluded from this
study.

- Patients must have a Karnofsky performance status greater than 70%.

- DLCO >=60% predicted.

- ALT and AST must be < 2X normal. Total bilirubin less than 2 mg/dl.

- Serum creatinine < 2.0 or 24-hour creatinine clearance >=60 ml/min.

- Patients must be HIV negative.

- Pregnant or lactating women will not be eligible to participate.

- Patients must provide signed, informed consent.

- Patients must have an HLA-identical sibling donor.

Exclusion Criteria:

- Severe psychological or medical illness

- Patients who have undergone prior allogeneic hematopoietic cell transplantation will
not be eligible for this study.